CoChat

Timing of Estradiol Treatment After Menopause May Determine Benefit or Harm to Insulin Action

Open access
Pereira, R. I., Casey, B. A., Swibas, T. A., Erickson, C. B., Wolfe, P., Van Pelt, R. E. · 2015 · The Journal of Clinical Endocrinology & Metabolism

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

CONTEXT: Type 2 diabetes (T2D) is reduced in postmenopausal women randomized to estrogen-based hormone therapy (HT) compared with placebo. Insulin sensitivity is a key determinant of T2D risk and overall cardiometabolic health, and studies indicate that estradiol (E2) directly impacts insulin action. OBJECTIVE: We hypothesized that the timing of E2 administration after menopause is an important determinant of its effect on insulin action. DESIGN: We performed a randomized, crossover, placebo-controlled study. PARTICIPANTS: Study participants were early postmenopausal (EPM; ≤ 6 years of final menses; n = 22) and late postmenopausal (LPM; ≥ 10 years since last menses; n = 24) women naive to HT. INTERVENTION: Study interventions included short-term (1 week) transdermal E2 and placebo. MAIN OUTCOMES AND MEASURES: The study's main outcome was insulin-mediated glucose disposal (glucose disposal rate [GDR]) via hyperinsulinemic-euglycemic clamp. RESULTS: Compared to EPM women, LPM women were older (mean ± SD; 63 ± 3 vs 56 ± 4 years, P < .05) and more years past menopause (12 ± 2 vs 3 ± 2 years, P < .05). Body mass index (24 ± 3 vs 25 ± 7 kg/m(2)) and fat mass (25 ± 7 vs 23 ± 6 kg) did not differ between groups, but fat-free mass (FFM) was lower in LPM women compared to EPM women (40 ± 4 vs 43 ± 5 kg, P < .05). Baseline GDR did not differ between groups (11.7 ± 2.8 vs 11.5 ± 2.9 mg/kg FFM/min). In support of our hypothesis, 1 week of E2 decreased GDR in LPM women compared to an increase in EPM women (+0.44 ± 1.7 vs - 0.76 ± 2.1 mg/kg FFM/min, P < .05). CONCLUSIONS: There was not an apparent decline in GDR with age or time since menopause per se. However, E2 action on GDR was dependent on time since menopause, such that there was an apparent benefit early (≤ 6 years) compared to harm later (≥ 10 years) in menopause. E2-mediated effects on insulin action may be one mechanism by which HT reduces the incidence of T2D in early postmenopausal women.

Overview

Integrity signals

Registry

Crossref · 10.1210/jc.2015-3084

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 42 references

Cited by

See all 71

Metadata

Authors
Pereira, R. I., Casey, B. A., Swibas, T. A., Erickson, C. B., Wolfe, P., & Van Pelt, R. E.
Affiliations
  • Division of Geriatric Medicine; Department of Medicine (R.I.P., B.A.C.), Division of Endocrinology, Metabolism and Diabetes
  • Department of Medicine (T.A.S., C.B.E., R.E.V.P.), Aurora, Colorado 80045
  • Colorado School of Public Health (US)
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2015-12-01
Volume
100
Issue
12
Pages
4456-4462
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W1680854225
Cited by
59
References
42
Citations by year
2026: 3 · 2025: 6 · 2024: 2 · 2023: 4 · 2022: 7 · 2021: 2 · 2020: 3 · 2019: 7 · 2018: 4 · 2017: 16 · 2016: 5
FWCI
7.23
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institute for Health and Care Research
  • National Institutes of Health (UL1TR000154, UL1TR001082)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK088105, T32DK007446, P30DK048520)
  • National Center for Advancing Translational Sciences
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (P50HD073063)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords
estradiol, hormone therapy, menopause, insulin sensitivity, glucose disposal rate, type 2 diabetes risk, postmenopausal women, timing of hormone therapy, transdermal estradiol, fat-free mass, hyperinsulinemic-euglycemic clamp, cardiometabolic health, age at menopause, body composition, skeletal muscle
MeSH terms
Age Factors, Aged, Body Composition, Diabetes Mellitus, Type 2, Estradiol, Female, Glucose, Glucose Tolerance Test, Humans, Insulin Resistance, Middle Aged, Motor Activity, Glucose Clamp Technique, Estrogen Replacement Therapy, Body Mass Index, Treatment Outcome, Postmenopause, Cross-Over Studies, Risk Reduction Behavior, Adiposity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Timing of Estradiol Treatment After Menopause May Determine Benefit or Harm to Insulin Action. https://app.cochat.ai/papers/10.1210/jc.2015-3084
The paper
Pereira, R. I., Casey, B. A., Swibas, T. A., Erickson, C. B., Wolfe, P., & Van Pelt, R. E. (2015). Timing of Estradiol Treatment After Menopause May Determine Benefit or Harm to Insulin Action. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2015-3084

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.